Meeting
2020 Gastrointestinal Cancers Symposium
Homologous recombination deficiency (HRD) scoring in pancreatic ductal adenocarcinoma (PDAC) and response to chemotherapy.
Authors
Grainne M. O'Kane
Princess Margaret Cancer Centre, Toronto, ON, Canada
Grainne M. O'Kane , Rob Denroche , Sarah Louise Picardo , Amy Zhang , Spring Holter , Robert C. Grant , Michael Allen , Yifan Wang , Anna Dodd , Stephanie Ramotar , Shawn Hutchinson , Mustapha Tehfe , James Joseph Biagi , Julie Wilson , Faiyaz Notta , Sandra Fischer , George Zogopoulos , Steven Gallinger , Jennifer J. Knox
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT02750657
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 741)
Abstract #
741
Poster Bd #
M8
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience.
First Author: Amy E. Chang
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2022 ASCO Annual Meeting
The impact of HRD in patients with pancreatic adenocarcinoma undergoing surgical resection: An updated analysis.
First Author: Gudbjorg Jonsdottir
Poster
2022 ASCO Annual Meeting
Evaluation of stage IV pancreatic adenocarcinomas based on mutational profiling of tumors.
First Author: Katherine E Poruk